Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends [Yahoo! Finance]
Organon & Co. (OGN)
Company Research
Source: Yahoo! Finance
Organon extended its winning streak to a third straight day on Monday, jumping 13.72 percent to close at $7.71 as investors snapped up shares ahead of the record date for its next quarterly dividend payment, despite weak earnings results for the third quarter. In an updated report, Organon & Co. (NYSE:OGN) said it would distribute $0.02 worth of dividends to all common shareholders as of November 20, 2025, payable on December 11, 2025. This followed the results of its earnings performance in the third quarter of the year, where it registered $160 million in net income, lower by 55 percent than the $359 million in the same period last year. Revenues, on the other hand, inched up by 1 percent to $1.6 billion from $1.58 billion year-on-year, on the back of higher revenues from general medicines, which offset the drop in revenues from women's health. Following the results, Organon & Co. (NYSE:OGN) lowered its revenue guidance for full-year 2025 to a range of $6.2 billion to $6.25
Show less
Read more
Impact Snapshot
Event Time:
OGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGN alerts
High impacting Organon & Co. news events
Weekly update
A roundup of the hottest topics
OGN
News
- Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]Yahoo! Finance
- Organon To Present at the Piper Sandler 37th Annual Healthcare ConferenceBusiness Wire
- Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the USPR Newswire
- Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the USBusiness Wire
- Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGNBusiness Wire
OGN
Earnings
- 11/10/25 - Beat
OGN
Sec Filings
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- 11/12/25 - Form 4
- OGN's page on the SEC website